JPWO2020030593A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020030593A5
JPWO2020030593A5 JP2021506287A JP2021506287A JPWO2020030593A5 JP WO2020030593 A5 JPWO2020030593 A5 JP WO2020030593A5 JP 2021506287 A JP2021506287 A JP 2021506287A JP 2021506287 A JP2021506287 A JP 2021506287A JP WO2020030593 A5 JPWO2020030593 A5 JP WO2020030593A5
Authority
JP
Japan
Prior art keywords
composition according
antibiotic
polymyxin
cephalosporins
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021506287A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533150A (ja
JP2021533150A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/071026 external-priority patent/WO2020030593A1/en
Publication of JP2021533150A publication Critical patent/JP2021533150A/ja
Publication of JPWO2020030593A5 publication Critical patent/JPWO2020030593A5/ja
Publication of JP2021533150A5 publication Critical patent/JP2021533150A5/ja
Pending legal-status Critical Current

Links

JP2021506287A 2018-08-05 2019-08-05 移植片対宿主病の治療のための組成物 Pending JP2021533150A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18187409 2018-08-05
EP18187409.0 2018-08-05
PCT/EP2019/071026 WO2020030593A1 (en) 2018-08-05 2019-08-05 Compositions for the treatment of graft versus host disease

Publications (3)

Publication Number Publication Date
JP2021533150A JP2021533150A (ja) 2021-12-02
JPWO2020030593A5 true JPWO2020030593A5 (https=) 2022-06-27
JP2021533150A5 JP2021533150A5 (https=) 2022-06-27

Family

ID=63165229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021506287A Pending JP2021533150A (ja) 2018-08-05 2019-08-05 移植片対宿主病の治療のための組成物

Country Status (11)

Country Link
US (1) US20210290741A1 (https=)
EP (1) EP3829552A1 (https=)
JP (1) JP2021533150A (https=)
KR (1) KR20210040395A (https=)
CN (1) CN112689506A (https=)
AU (1) AU2019320483A1 (https=)
BR (1) BR112021002105A2 (https=)
CA (1) CA3106433A1 (https=)
IL (1) IL280589A (https=)
MX (1) MX2021001393A (https=)
WO (1) WO2020030593A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220218800A1 (en) * 2019-05-06 2022-07-14 Synthetic Biologics, Inc. Beta-lactamase compositions for treatment of graft versus host disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249100B2 (en) 2005-05-18 2012-01-19 Assistance Publique - Hospitaux De Paris Colonic delivery of adsorbents
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
FI119190B (fi) 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
MX340822B (es) 2010-02-23 2016-07-26 Da Volterra * Formulaciones para suministro oral de adsorbentes en el intestino.
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
EP2897594B1 (en) 2012-09-21 2020-04-08 Ferring B.V. Pharmaceutical composition
US9290754B2 (en) 2014-04-17 2016-03-22 Synthetic Biologics Inc. Beta-lactamases with improved properties for therapy
CN107148473B (zh) * 2014-10-08 2021-08-06 合成生物制品有限公司 β-内酰胺酶制剂及其用途
FR3027307B1 (fr) 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
CA3254897A1 (en) * 2014-11-25 2026-03-02 Memorial Sloan-Kettering Cancer Center Intestinal microbiota and gvhd
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome

Similar Documents

Publication Publication Date Title
Mader et al. Antimicrobial treatment of chronic osteomyelitis
JP5964854B2 (ja) 抗菌剤と分散剤または接着阻害剤組成物
EP0671942B1 (en) Pharmaceutical preparation comprising a beta-lactam antibiotic degrading compound, and use thereof
EP4115897A1 (en) Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
CN110520114B (zh) 包含银和抗生素的纳米体系及其用于治疗细菌感染的用途
JP2003321389A5 (https=)
CN101175531B (zh) 包含一种抗菌药以及一种选自香芹醇、麝香草酚、丁香酚、冰片、香芹酚的活性物质的药物组合物
EP1044006B1 (en) Use of an antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection
AU2017203136A1 (en) Methods for treating bacterial infection
JP2021533150A5 (https=)
JPWO2020030593A5 (https=)
RU2021105528A (ru) Композиции для лечения реакции трансплантат против хозяина
EP1003554B1 (en) Proton pump inhibitor in therapeutic combination with antibacterial substances
US20210290741A1 (en) Compositions for the treatment of graft versus host disease
JP2021534091A (ja) 抗がん剤の有効性を改善する方法
GB2490671A (en) Pharmaceutical preparation and use